Publicações
A comunicação dos resultados da nossa investigação é fundamental. Esta preocupação reflete-se no nível de publicações em jornais e revistas com fator de impacto e no número de pósteres e apresentações nos principais congressos mundiais, particularmente nas neurociências.
Consulte abaixo exemplos de publicações, alguns de autoria ou co-autoria de cientistas BIAL.
- Acetato de Eslicarbazepina
- Opicapona
- Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Authors: Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, et al.
Published: Epilepsia [Internet]. 2018;59(2):479–91. - Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.
Authors: Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P. Safety, Tolerability and Efficacy of Eslicarbazepine
Published: Drugs Aging [Internet]. 2018;null–null. - Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
Authors: Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P.
Published: Epilepsy & behavior : E&B [Internet]. 2018;81:1–11. - Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study.
Authors: Christian Elger.
Published: Epilepsia. 2009;50(3):454–63. - Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Authors: E. Ben-Menachem.
Published: Epilepsy Res Suppl. 2010;89(2-3):278–85. - Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.
Authors: A. Gil-Nagel.
Published: Acta Neurol Scand. 2009;120(5):281–7. - Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Authors: Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, et al.
Published: Epilepsia [Internet]. 2015;56(2):244–53.
- Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: A pooled-analysis of data from two Phase 3 clinical trials and their open-label extensions.
Authors: Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.
Published: Eur J Neurol [Internet]. 2019;null–null. - Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
Authors: Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, et al.
Published: Neurology [Internet]. 2018;90(21):e1849–e1857. - Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Authors: Ferreira JJ.
Published: Lancet Neurol. 2016;15(2):154–65. - Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Authors: Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, et al.
Published: Eur J Clin Pharmacol [Internet]. 2014;70(9):1059–71. - Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Authors: Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al.
Published: JAMA Neurol [Internet]. 2017;74(2):197–206.
Está a sair do site da BIAL.
BIAL assume a responsabilidade pelos conteúdos do seu site. Ao clicar em "Continuar", em baixo, entrará num website externo a BIAL e fora do seu âmbito de responsabilidade.